188 related articles for article (PubMed ID: 25418578)
41. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
43. Gene expression profiling of diffuse large B-cell lymphoma.
Rosenwald A; Staudt LM
Leuk Lymphoma; 2003; 44 Suppl 3():S41-7. PubMed ID: 15202524
[TBL] [Abstract][Full Text] [Related]
44. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
[TBL] [Abstract][Full Text] [Related]
45. Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology.
Skaftason A; Qu Y; Abdulla M; Nordlund J; Berglund M; Ednersson SB; Andersson PO; Enblad G; Amini RM; Rosenquist R; Mansouri L
Genes Chromosomes Cancer; 2022 Jan; 61(1):27-36. PubMed ID: 34647650
[TBL] [Abstract][Full Text] [Related]
46. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.
Mullins M; Perreard L; Quackenbush JF; Gauthier N; Bayer S; Ellis M; Parker J; Perou CM; Szabo A; Bernard PS
Clin Chem; 2007 Jul; 53(7):1273-9. PubMed ID: 17525107
[TBL] [Abstract][Full Text] [Related]
47. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
48. Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.
Decruyenaere P; Giuili E; Verniers K; Anckaert J; De Grove K; Van der Linden M; Deeren D; Van Dorpe J; Offner F; Vandesompele J
Front Oncol; 2023; 13():1221471. PubMed ID: 37954086
[TBL] [Abstract][Full Text] [Related]
49. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.
Ruminy P; Etancelin P; Couronné L; Parmentier F; Rainville V; Mareschal S; Bohers E; Burgot C; Cornic M; Bertrand P; Lenormand B; Picquenot JM; Jardin F; Tilly H; Bastard C
Leukemia; 2011 Apr; 25(4):681-8. PubMed ID: 21233831
[TBL] [Abstract][Full Text] [Related]
50. Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.
Viswanathan A; Kundal K; Sengupta A; Kumar A; Kumar KV; Holmes AB; Kumar R
Brief Funct Genomics; 2023 Jan; 22(1):42-48. PubMed ID: 36412115
[TBL] [Abstract][Full Text] [Related]
51. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
Yao XX; Wang JF; Wang YH; Gao N
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
[TBL] [Abstract][Full Text] [Related]
52. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
Cao QW; Li HY; Yao XX; Wang JF
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
[TBL] [Abstract][Full Text] [Related]
53. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
54. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
55. Increased sensitivity of B-cell clonality analysis in formalin-fixed and paraffin-embedded B-cell lymphoma samples using an enzyme blend with both 5'-->3' DNA polymerase and 3'-->5' exonuclease activity.
Gurbity TP; Bagdi E; Groen NA; Budel LM; Abbou M; Krenacs L; Dinjens WN
Virchows Arch; 2003 Nov; 443(5):643-8. PubMed ID: 12937979
[TBL] [Abstract][Full Text] [Related]
56. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
57. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
[TBL] [Abstract][Full Text] [Related]
58. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].
Škunca Z; Planinc-Peraica A
Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782
[TBL] [Abstract][Full Text] [Related]
59. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
Bea S; Zettl A; Wright G; Salaverria I; Jehn P; Moreno V; Burek C; Ott G; Puig X; Yang L; Lopez-Guillermo A; Chan WC; Greiner TC; Weisenburger DD; Armitage JO; Gascoyne RD; Connors JM; Grogan TM; Braziel R; Fisher RI; Smeland EB; Kvaloy S; Holte H; Delabie J; Simon R; Powell J; Wilson WH; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Campo E; Rosenwald A;
Blood; 2005 Nov; 106(9):3183-90. PubMed ID: 16046532
[TBL] [Abstract][Full Text] [Related]
60. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
